Today’s Watch List: Exlservice Holdings, Inc.

Exlservice Holdings, Inc. (NASDAQ:EXLS) announced its financial results for the fourth quarter and full year 2015 and provided guidance for full year 2016. In the fourth quarter, EXL had revenues of $165.9 million, an increase of 22.6% from fourth quarter 2014 (15.3% excluding disentanglement costs) and an increase of 1.4% sequentially. In the fourth quarter, EXL delivered diluted EPS of $0.43 and adjusted diluted EPS of $0.56.

Exlservice Holdings, Inc. (NASDAQ:EXLS) belongs to Services sector. Its net profit margin is 7.40% and weekly performance is 8.01%. On last trading day company shares ended up at $48.57. Exlservice Holdings, Inc. (NASDAQ:EXLS) distance from 50-day simple moving average (SMA50) is -7.41%.

Second Sight Medical Products, Inc. (NASDAQ:EYES) announced it will unveil five-year outcomes associated with the Argus® II Retinal Prosthesis System (“Argus II”) during the 39th Annual Macula Society Meeting, being held February 24-27, 2016, at Eden Roc Miami Beach.

Second Sight Medical Products, Inc. (NASDAQ:EYES) shares advanced 28.36% in last trading session and ended the day at $6.79. EYES Gross Margin is 38.30% and its return on assets is -73.80%. Second Sight Medical Products, Inc. (NASDAQ:EYES) quarterly performance is 36.07%.

Alkermes plc (NASDAQ:ALKS) announced the initiation of ENLIGHTEN-2, the second of two core phase 3 studies for ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia. ENLIGHTEN-2 will evaluate the weight gain profile of ALKS 3831 in patients with schizophrenia over a six-month treatment period compared to olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain.

On 23 February, Alkermes plc (NASDAQ:ALKS) shares advanced 0.26% and was closed at $34.10. ALKS EPS growth in last 5 year was 12.90%. Alkermes plc (NASDAQ:ALKS) year to date (YTD) performance is -57.04%.

Genocea Biosciences Inc (NASDAQ:GNCA)‘s stock had its “outperform” rating restated by equities researchers at FBR & Co. in a research note issued to investors on Friday, Analyst Ratings Net reports. They currently have a $17.00 target price on the stock. FBR & Co.’s price target points to a potential upside of 364.48% from the company’s current price.

Genocea Biosciences, Inc. (NASDAQ:GNCA) ended the last trading day at $3.60. Company weekly volatility is calculated as 11.31% and price to cash ratio as 1.07. Genocea Biosciences, Inc. (NASDAQ:GNCA) showed a weekly performance of -6.74%.

International Business Machines Corporation (NYSE:IBM) announced a cash dividend payment of $1.3 per share is scheduled to be paid on March 10, 2016. Shareholders who purchased IBM prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that IBM has paid the same dividend.

International Business Machines Corporation (NYSE:IBM) belongs to Technology sector. Its net profit margin is 16.10% and weekly performance is 7.87%. On last trading day company shares ended up at $132.40. International Business Machines Corporation (NYSE:IBM) distance from 50-day simple moving average (SMA50) is 2.31%.

Leave a Reply

Your email address will not be published. Required fields are marked *